X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (30) 30
hygiene (29) 29
medical or veterinary science (29) 29
preparations for medical, dental, or toilet purposes (29) 29
chemistry (24) 24
metallurgy (24) 24
organic chemistry (22) 22
specific therapeutic activity of chemical compounds ormedicinal preparations (20) 20
heterocyclic compounds (18) 18
general tagging of cross-sectional technologies spanning over several sections of the ipc (14) 14
general tagging of new technological developments (14) 14
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (14) 14
technologies for adaptation to climate change (14) 14
technologies or applications for mitigation or adaptation againstclimate change (14) 14
animals (13) 13
humans (10) 10
cancer (7) 7
index medicus (7) 7
rats (7) 7
oncology (6) 6
beer (5) 5
biochemistry (5) 5
compositions thereof (5) 5
culture media (5) 5
enzymology (5) 5
hela cells (5) 5
mice (5) 5
microbiology (5) 5
microorganisms or enzymes (5) 5
mutation or genetic engineering (5) 5
propagating, preserving or maintaining microorganisms (5) 5
spirits (5) 5
vinegar (5) 5
wine (5) 5
breast cancer (4) 4
cell cycle (4) 4
centrosome - metabolism (4) 4
female (4) 4
investigating or analysing materials by determining theirchemical or physical properties (4) 4
measuring (4) 4
peptides (4) 4
physics (4) 4
poly polymerase (4) 4
proteins (4) 4
testing (4) 4
agriculture (3) 3
animal husbandry (3) 3
article (3) 3
biocides, e.g. as disinfectants, as pesticides, as herbicides (3) 3
cell biology (3) 3
cell line, tumor (3) 3
chemistry, medicinal (3) 3
fishing (3) 3
forestry (3) 3
homologous recombination (3) 3
hunting (3) 3
parp (3) 3
pest repellants or attractants (3) 3
phospholipase a (3) 3
phosphorylation (3) 3
plant growth regulators (3) 3
preservation of bodies of humans or animals or plants or partsthereof (3) 3
repair (3) 3
trapping (3) 3
tumors (3) 3
12-hydroxy-5,8,10,14-eicosatetraenoic acid - pharmacology (2) 2
administration, oral (2) 2
alanine - analogs & derivatives (2) 2
alanine - pharmacology (2) 2
antitumor-activity (2) 2
apoptosis (2) 2
binding (2) 2
binding sites (2) 2
biochemistry & molecular biology (2) 2
biology (2) 2
biomarkers (2) 2
bioscience (2) 2
brca1 protein (2) 2
breast (2) 2
caco-2 cells (2) 2
calcium (2) 2
cancer-cells (2) 2
cell (2) 2
cell adhesion - drug effects (2) 2
cell line (2) 2
cells, cultured (2) 2
centrosome amplification (2) 2
chemistry, organic (2) 2
colon (2) 2
cycle (2) 2
cyclin a - metabolism (2) 2
deoxyribonucleic acid--dna (2) 2
discovery (2) 2
dna damage (2) 2
dna repair (2) 2
dna-damage (2) 2
drug discovery (2) 2
enzyme activation - drug effects (2) 2
enzymes (2) 2
fetal-rat-brain (2) 2
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (65) 65
French (9) 9
German (4) 4
Chinese (3) 3
Japanese (3) 3
Croatian (1) 1
Danish (1) 1
Greek (1) 1
Hungarian (1) 1
Polish (1) 1
Portuguese (1) 1
Slovenian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2015, Volume 14, Issue 12 Supplement 2, pp. B168 - B168
Journal Article
Trends in Cell Biology, ISSN 0962-8924, 2005, Volume 15, Issue 6, pp. 303 - 311
Early observations of centrosomes, made a century ago, revealed a tiny dark structure surrounded by a radial array of cytoplasmic fibers. We now know that the... 
Tubulin - metabolism | Animals | Cell Cycle | Signal Transduction | Humans | Aneuploidy | Centrosome - metabolism | Proteins
Journal Article
Cancer Research, ISSN 0008-5472, 02/2018, Volume 78, Issue 3, pp. 742 - 757
PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients. Several of those patients exhibit intrinsic/acquired resistance mechanisms that... 
STEM-CELLS | DINACICLIB SCH 727965 | ONCOLOGY | DNA-DAMAGE RESPONSE | IN-VIVO | TRANSCRIPTION | C-MYC | RESISTANCE | HOMOLOGOUS RECOMBINATION | DEPENDENT KINASE INHIBITOR | OVARIAN-CARCINOMA | Cell Proliferation | Humans | Synthetic Lethal Mutations | Triple Negative Breast Neoplasms - drug therapy | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Pyridinium Compounds - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Triple Negative Breast Neoplasms - genetics | Mice, Nude | DNA Repair | Proto-Oncogene Proteins c-myc - antagonists & inhibitors | Triple Negative Breast Neoplasms - pathology | Female | Mice | DNA Damage | Tumor Cells, Cultured | Drug Therapy, Combination | BRCA2 Protein - genetics | Apoptosis | Mesenchyme | Lung cancer | DNA damage | Homologous recombination | c-Myc protein | Homology | Lethality | Myc protein | Kinases | DNA repair | Cyclin-dependent kinase | Colon cancer | Colon | Pancreas | Repair | Deoxyribonucleic acid--DNA | Effectiveness | Poly(ADP-ribose) polymerase | Breast cancer | Gene expression | Patients | Inhibitors | Addiction | Pancreatic cancer | Biomarkers | Breast | Prostate | Tumors | Cancer | Synthetic Lethal | PARP | RAD51 | TNBC | MYC
Journal Article
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2019, Volume 9, Issue 1, pp. 1853 - 12
PARP inhibitors have been proven clinically efficacious in platinum-responsive ovarian cancer regardless of BRCA1/2 status and in breast cancers with germline... 
BREAST-CANCER | GAMMA | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | DNA-DAMAGE | DOUBLE-BLIND | OVARIAN-CANCER | BLOCKADE | EXPRESSION | MAINTENANCE THERAPY | T-CELLS | Animal models | Immunological memory | BRCA1 protein | PD-1 protein | Immunomodulation | CD8 antigen | Poly(ADP-ribose) polymerase | Breast cancer | Ovarian cancer | Metastases | CD4 antigen | Poly(ADP-ribose) Polymerase 1 | Immune checkpoint | Platinum | Interferon | Tumors
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 1724 - 1724
Journal Article
Cancer Research, ISSN 0008-5472, 12/2018, Volume 78, Issue 23, pp. 6691 - 6702
PARP proteins represent a class of post-translational modification enzymes with diverse cellular functions. Targeting PARPs has proven to be efficacious... 
CELLS | POLY(ADP-RIBOSE) | CHK1 | ONCOLOGY | CENTROSOME AMPLIFICATION | DNA-DAMAGE | TARGETS | DISCOVERY
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 5690 - 5690
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 4353 - 4353
Poly-ADP-ribose polymerase 1 (PARP) inhibitors are therapeutically effective in a subset of breast and high-grade ovarian cancers harboring deleterious BRCA12... 
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 12/2015, Volume 25, Issue 24, pp. 5743 - 5747
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 5826 - 5826
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2015, Volume 14, Issue 12 Supplement 2, pp. B169 - B169
Journal Article
2004, AD-a426 156.
Breast tumors are aneuploid and contain high pericentrin levels. The ABC kinases, known individually as protein kinases A, B (akt), and C have each been linked... 
pericentrin | in vivo analysis | biomarkers | chromosomes | breast cancer | enzymes | centrosomes | oncology | mammary glands | in vitro analysis | phosphorus transferases | proteins | instability | aneuploid | neoplasms | linkages | phosphorylation
Government Document
Oncotarget, ISSN 1949-2553, 12/2018, Volume 9, Issue 98, pp. 37080 - 37096
Niraparib is an orally bioavailable and selective poly (ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of both mutant (mut)... 
Niraparib | Brain exposure | Tumor exposure | BRCAwt tumor | Intracranial tumor
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.